CONTACT
+91 80 2808 2808
info@biocon.com

Company Statement on US-FDA Inspection at Biocon Malaysia

  • Posted by: BIOCON

21st February 2018

“The US-FDA has completed a pre-approval inspection of our manufacturing facility in Malaysia and issued a Form 483 with 6 observations. As per the normal expectations of the agency, we intend to respond with a corrective and preventive action plan in a timely manner.” – Biocon Spokesperson.

Author: BIOCON
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>